Q: Hello Peter
I own Alergan stock and Pfizer & Alergan announced today 160 billion merger
The deal values Allergan at $363.63 per share, about 30% more than its price when reports of a deal first surfaced last month.
Allergan shareholders will get 11.3 shares of the new company for each of their shares. Pfizer shareholders will get one share of the new company’s stock for each of their shares.
After completion of the deal, which must be approved by U.S. and European regulators, Pfizer shareholders would own 56% of the combined company.
My question is what should I do with my shares, sell or wait for closing of the deal and what is good and what is bad in this deal for me as a shareholder.
Regards Andrew B.
I own Alergan stock and Pfizer & Alergan announced today 160 billion merger
The deal values Allergan at $363.63 per share, about 30% more than its price when reports of a deal first surfaced last month.
Allergan shareholders will get 11.3 shares of the new company for each of their shares. Pfizer shareholders will get one share of the new company’s stock for each of their shares.
After completion of the deal, which must be approved by U.S. and European regulators, Pfizer shareholders would own 56% of the combined company.
My question is what should I do with my shares, sell or wait for closing of the deal and what is good and what is bad in this deal for me as a shareholder.
Regards Andrew B.